Kyowa Hakko Bio Partners with the Agency for Science, Technology and Research (A*STAR) to Study
Human Milk Oligosaccharides (HMOs)[Tokyo, Japan] – January 16, 2024. – Kyowa Hakko Bio, a global leader in biotechnology and nutriOonalsoluOons, is thrilled to announce a groundbreaking collaboraOon with the Agency for Science,
Technology and Research (A*STAR) to advance research on Human Milk Oligosaccharides (HMOs), acrucial component of human breast milk.
HMOs are complex carbohydrates found exclusively in human breast milk known to play a signiﬁcant rolein infant health and development. Kyowa Hakko Bio has been at the forefront of HMO research anddevelopment, and this partnership with A*STAR will enhance our understanding of these essenOal
compounds and explore their potenOal applicaOons, including the promoOon of a healthy gut
microbiome and immune system.
As part of this collaboraOon, researchers from A*STAR’s Singapore InsOtute for Clinical Sciences (SICS)
will work closely with Kyowa Hakko Bio's biotechnology and nutriOon team. Leveraging SICS' extensive
experOse in unravelling factors that impact human health across lifespan, the two teams will jointly
undertake cuYng-edge studies aimed at unlocking the full potenOal of HMOs in promoOng health andwell-being.
Key objecOves of the collaboraOon include uncovering the potenOal beneﬁts of HMOs, such as
promoOng gut health through the growth of good bacteria in the gut and supporOng immune regulaOon.

Dr. Eri Nakazaki, Senior ScienOst and Manager of Corporate Strategy Department at Kyowa Hakko Bio,
expressed enthusiasm about this collaboraOon, saying, "Our partnership with A*STAR marks an exciOngchapter in our ongoing commitment to exploring the beneﬁts of HMOs. We believe that thiscollaboraOon will yield valuable insights that can beneﬁt people of all ages."

Prof Jeroen Schmia, Senior Principal InvesOgator at A*STAR’s SICS added, "We are excited to work
alongside Kyowa Hakko Bio in this pioneering research endeavor. Together, we aim to deepen our
understanding of HMOs and their potenOal applicaOons, ulOmately contribuOng to advancements inhealthcare and nutriOon."This collaboraOon exempliﬁes Kyowa Hakko Bio's dedicaOon to advancing scienOﬁc knowledge andimproving human health through innovaOve research and development iniOaOves.

For media inquiries or more informaOon about this collaboraOon, please contact:

Press Contact

Corporate CommunicaOon Department Kirin Holdings Company, Limited
Nakano Central Park South, 4-10-2 Nakano, Nakano-ku, Tokyo
haps://www.kirinholdings.com/en/
kirin-cc@kirin.co.jp

About Kirin Holdings
Kirin Holdings Company, Limited is an internaOonal company that operates in the Food & Beverages
domain (Food & Beverages businesses), PharmaceuOcals domain (PharmaceuOcals businesses), andHealth Science domain (Health Science business), both in Japan and across the globe.
Kirin Holdings can trace its roots to Japan Brewery which was established in 1885. Japan Brewery
became Kirin Brewery in 1907. Since then, the company expanded its business with fermentaOon andbiotechnology as its core technologies, and entered the pharmaceuOcal business in the 1980s, all ofwhich conOnue to be global growth centers. In 2007, Kirin Holdings was established as a pure holding
company and is currently focusing on boosOng its Health Science domain.
Under the Kirin Group Vision 2027 (KV 2027), a long-term management plan launched in 2019, the Kirin
Group aims to become A global leader in CSV*, creaOng value across our world of Food & Beverages toPharmaceuOcals. Going forward, the Kirin Group will conOnue to leverage its strengths to create bothsocial and economic value through its businesses, with the aim of achieving sustainable growth incorporate value.
* CreaOng Shared Value: combined added value for consumers as well as for society at large.

About Kyowa Hakko Bio:
Kyowa Hakko Bio Co. Ltd., an internaOonal health ingredients manufacturer and world leader in thedevelopment, manufacturing, and markeOng of pharmaceuOcals, nutraceuOcals, and food & beverage
products. Kyowa is the maker of branded ingredients, including IMMUSE™ LC-Plasma, Eyemuse™
LacOcaseibacillus paracasei KW3110, Cognizin® CiOcoline, Pantesin® Pantethine, Setria® Glutathione, as
well as L-Alanyl-L-Glutamine. For more informaOon, visit KYOWA HAKKO BIO CO.,LTD. (kyowahakkobio.co.jp).